Status:
UNKNOWN
PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer
Lead Sponsor:
Lei Li
Conditions:
Immune Checkpoint Inhibitors
Anti-programmed Death-1 Antibody
Eligibility:
FEMALE
18+ years
Brief Summary
This study is to investigate retrospectively the effects of combination of immune checkpoint inhibitors anti-programmed death-1 antibody (PD-1 antibody) and radiotherapy for recurrent, metastatic and ...
Eligibility Criteria
Inclusion
- Aged 18 years or older
- Confirmed of recurrent, metastatic, and persistent advanced cervical cancer
- Confirmed of subtypes of cervical squamous carcinoma, adenocarcinoma and adenosquamous carcinoma
- Accepting radiotherapy with concurrent anti PD-1 therapy
- With detailed follow-up outcomes
Exclusion
- \- Not meeting all of the inclusion criteria
Key Trial Info
Start Date :
March 26 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 26 2023
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05310305
Start Date
March 26 2022
End Date
March 26 2023
Last Update
April 11 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lei Li
Beijing, Beijing Municipality, China, 100730